Analyses of tumor biomarkers in clinical studies across various tumor types have identified factors that associate with response to ICB, including expression of PD-L1 on both tumor cells and tumor-infiltrating lymphocytes (TILs), tumor mutational burden, and TIL density, location, and activation (2). The gene discussed is CD274; the disease is neoplasm.